BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saponara M, Urbini M, Astolfi A, Indio V, Ercolani G, Del Gaudio M, Santini D, Pirini MG, Fiorentino M, Nannini M, Lolli C, Mandrioli A, Gatto L, Brandi G, Biasco G, Pinna AD, Pantaleo MA. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget 2015;6:42243-57. [PMID: 26544626 DOI: 10.18632/oncotarget.6278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Gao F, Wang J, Li C, Xie C, Su M, Zou C, Xie X, Zhao D. Risk-Related Genes and Associated Signaling Pathways of Gastrointestinal Stromal Tumors. IJGM 2022;Volume 15:3839-49. [DOI: 10.2147/ijgm.s357224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nowak K, Formenti K, Huang J, Bigras G, Chu Q, Adam BA, Izevbaye I. Risk stratification of gastrointestinal stromal tumors by Nanostring gene expression profiling. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-03924-3] [Reference Citation Analysis]
3 Lv BB, Li JM, Yao ZG, Cheng XK, Ren FX, Su WJ, Qin YJ, Wang Z, Cao ZX. Succinate dehydrogenase deficient gastrointestinal stromal tumor in a three month old boy with a fatal clinical course: a case report and review of literature. Diagn Pathol 2021;16:14. [PMID: 33612108 DOI: 10.1186/s13000-021-01077-4] [Reference Citation Analysis]
4 Pai T, Bal M, Shetty O, Gurav M, Ostwal V, Ramaswamy A, Ramadwar M, Desai S. Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience. South Asian J Cancer 2017;6:113-7. [PMID: 28975118 DOI: 10.4103/sajc.sajc_275_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Liang CW, Yang CY, Flavin R, Fletcher JA, Lu TP, Lai IR, Li YI, Chang YL, Lee JC. Loss of SFRP1 expression is a key progression event in gastrointestinal stromal tumor pathogenesis. Hum Pathol 2021;107:69-79. [PMID: 33186588 DOI: 10.1016/j.humpath.2020.10.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ohshima K, Fujiya K, Nagashima T, Ohnami S, Hatakeyama K, Urakami K, Naruoka A, Watanabe Y, Moromizato S, Shimoda Y, Ohnami S, Serizawa M, Akiyama Y, Kusuhara M, Mochizuki T, Sugino T, Shiomi A, Tsubosa Y, Uesaka K, Terashima M, Yamaguchi K. Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors. Cancer Sci 2019;110:3821-33. [PMID: 31553483 DOI: 10.1111/cas.14202] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
7 Iruzubieta P, Monzón M, Castiella T, Ramírez T, Junquera C. Hedgehog signalling pathway activation in gastrointestinal stromal tumours is mediated by primary cilia. Gastric Cancer 2020;23:64-72. [PMID: 31267361 DOI: 10.1007/s10120-019-00984-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hall F, Villalobos V, Wilky B. Future directions in soft tissue sarcoma treatment. Curr Probl Cancer 2019;43:300-7. [PMID: 31229264 DOI: 10.1016/j.currproblcancer.2019.06.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
9 Nannini M, Biasco G. Personalized Medicine in Gastrointestinal Stromal Tumors. Oncogenomics 2019. [DOI: 10.1016/b978-0-12-811785-9.00023-5] [Reference Citation Analysis]
10 Jing X M.D, Meng X M.D, Ph.D, Gao Y M.D, Ph.D, Yu J M.D, Ph.D, Liu B M.D, Ph.D. A 4-month-old boy with gastrointestinal stromal tumor of mesocolon. Cancer Biol Ther 2019;20:8-14. [PMID: 30252568 DOI: 10.1080/15384047.2018.1504719] [Reference Citation Analysis]
11 Hoffner B, Elias AD, Villalobos VM. Targeted Therapies in the Treatment of Sarcomas. Targ Oncol 2018;13:557-65. [DOI: 10.1007/s11523-018-0583-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tang CM, Lee TE, Syed SA, Burgoyne AM, Leonard SY, Gao F, Chan JC, Shi E, Chmielecki J, Morosini D, Wang K, Ross JS, Kendrick ML, Bardsley MR, Siena M, Mao J, Harismendy O, Ordog T, Sicklick JK. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. Oncotarget 2016;7:78226-41. [PMID: 27793025 DOI: 10.18632/oncotarget.12909] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
13 Wozniak A, Gebreyohannes YK, Debiec-Rychter M, Schöffski P. New targets and therapies for gastrointestinal stromal tumors. Expert Rev Anticancer Ther 2017;17:1117-29. [PMID: 29110548 DOI: 10.1080/14737140.2017.1400386] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
14 Kosemehmetoglu K, Kaygusuz G, Fritchie K, Aydin O, Yapicier O, Coskun O, Karatayli E, Boyacigil S, Guler G, Dervisoglu S, Kuzu I. Clinical and pathological characteristics of gastrointestinal stromal tumor (GIST) metastatic to bone. Virchows Arch. 2017;471:77-90. [PMID: 28488171 DOI: 10.1007/s00428-017-2138-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
15 Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci. 2017;108:547-552. [PMID: 28109176 DOI: 10.1111/cas.13173] [Cited by in Crossref: 115] [Cited by in F6Publishing: 121] [Article Influence: 23.0] [Reference Citation Analysis]
16 Sankhala KK. Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies. Expert Opin Investig Drugs 2017;26:427-43. [PMID: 28267385 DOI: 10.1080/13543784.2017.1303045] [Reference Citation Analysis]
17 Kondo T. Proteogenomics for the Study of Gastrointestinal Stromal Tumors. In: Végvári Á, editor. Proteogenomics. Cham: Springer International Publishing; 2016. pp. 139-51. [DOI: 10.1007/978-3-319-42316-6_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Noujaim J, Gonzalez D, Thway K, Jones RL, Judson I. p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib? Cancer Biol Ther 2016;17:543-5. [PMID: 26942271 DOI: 10.1080/15384047.2016.1156263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]